Sino Biopharma wins China NMPA approval for first-line squamous NSCLC combo therapy

• Sino Biopharmaceutical won China NMPA clearance for bevacizumab biosimilar Bemosunab with chemo, sequenced with anlotinib, in first-line sq-NSCLC.
• Approval was supported by the phase 3 ETER700 trial; median PFS was 11.2 months versus 8.28 months for the comparator regimen.
• Median OS was not reached versus 26.45 months; hazard ratio 0.75.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12277465), on August 07, 2026, and is solely responsible for the information contained therein.